SPHDF (Santhera Pharmaceuticals Holding AG) Retained Earnings: $-833.14 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPHDF Santhera Pharmaceuticals Holding AG SPHDF
39 GF Score
Price $23.25
GF Value $35.65
! 6 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Retained Earnings?

Santhera Pharmaceuticals Holding AG SPHDF 39 Retained Earnings is $-833.14 Mil as of Dec. 2025. GuruFocus rates SPHDF with a GF Score™ of 39/100 and a GF Value™ of $35.65. The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Santhera Pharmaceuticals Holding AG's retained earnings for the quarter that ended in Dec. 2025 was $-833.14 Mil.

Santhera Pharmaceuticals Holding AG's quarterly retained earnings declined from Dec. 2024 ($-689.43 Mil) to Jun. 2025 ($-803.65 Mil) and declined from Jun. 2025 ($-803.65 Mil) to Dec. 2025 ($-833.14 Mil).

Santhera Pharmaceuticals Holding AG's annual retained earnings declined from Dec. 2023 ($-662.26 Mil) to Dec. 2024 ($-689.43 Mil) and declined from Dec. 2024 ($-689.43 Mil) to Dec. 2025 ($-833.14 Mil).


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Santhera Pharmaceuticals Holding AG Retained Earnings Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG Retained Earnings Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -604.15 -673.57 -662.26 -689.43 -833.14

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -662.26 -657.85 -689.43 -803.65 -833.14
SPHDF
39GF Score
Santhera Pharmaceuticals Holding AG SPHDF
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-833.14 Mil mean?
Santhera Pharmaceuticals Holding AG (SPHDF) has a Retained Earnings of $-833.14 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Santhera Pharmaceuticals Holding AG and its competitors.
Is Santhera Pharmaceuticals Holding AG's Retained Earnings too high?
Santhera Pharmaceuticals Holding AG's current Retained Earnings is $-833.14 Mil. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Retained Earnings compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's Retained Earnings of $-833.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current Retained Earnings is $-833.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Santhera Pharmaceuticals Holding AG (SPHDF) has a current Retained Earnings of $-833.14 Mil. The stock's GF Value™ is $35.65, compared to a current price of $23.25 — trading 34.8% below its estimated fair value. The current Retained Earnings is $-833.14 Mil. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current Retained Earnings is $-833.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of $23.25 is trading 34.8% below its estimated GF Value™ of $35.65.

Key valuation signals for SPHDF:

  • Retained Earnings: $-833.14 Mil
  • GF Value™: $35.65 vs. price of $23.25 (34.8% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for SPHDF

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.25
Price
$35.65
GF Value